Life sciences · Journal article
Acs Applied Nano Materials · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Radiotherapy (RT) is crucial in the treatment of triple-negative breast cancer (TNBC). However, insufficient deposition of X-ray energy and peripheral tissue destruction usually caused RT failure. To circumvent this problem, herein, a “three-pronged strategy” nano-radiosensitizer (by encapsulating small molecules RSL3 and Gingerenone A (Gin A) in hollow Cu9S8 deposited with gold nanoparticles, RG@CSG) to combine with ferroptosis induction, G2/M arrest, and energy deposition is rationally designed. After passive accumulation of radiosensitizers at the tumor site, Au nanoparticles (Au NPs) grown on the surface can increase the deposition of X-ray energy to amplify the radiation-induced damage. Subsequently, upon X-ray irradiation, RG@CSG disintegrates to release RSL3 and Gin A. Gin A induces cell cycle arrest in the G2/M phase of tumor cells, which compromises DNA damage repair capacity and enhances tumor sensitivity to irradiation. RSL3 inactivates the GPX4-dependent ferroptosis defense system to eliminate residual tumor cells radioresistance. Furthermore, Au NPs can monitor the therapeutic response via activatable photoacoustic (PA) imaging in the NIR-II region (920 nm). Overall, the as-constructed RG@CSG enables a PA imaging-guided X-ray deposition-cell-cycle arrest-ferroptosis amplification cascade network, achieving a “triple-enhanced” RT sensitization strategy for effective TNBC therapy.